Medtronic Plc (NYSE:MDT) is headed into its June 3 earnings release with options markets pricing in a potential 4.1% stock movement, based on data compiled by Bloomberg. The anticipated move applies to the period around the company's pre-market earnings announcement.
Looking at recent history provides context for that implied swing. In six of Medtronic’s last eight earnings reports, the stock’s actual movement surpassed what options markets had predicted. The discrepancy between implied and realized moves highlights the potential for outsized volatility around the company’s results.
Outlined below are the most recent earnings reactions alongside the options-implied moves reported:
- On February 17, Medtronic shares fell 5.2% while the implied move was 3.6%.
- In November 2025, the stock climbed 8.8% versus an implied move of 3.6%.
- August 2025 earnings produced a 3.1% decline compared with a 3.5% implied move.
- May 2025 saw a 0.8% drop against a 3.0% implied move.
- February 2025 showed a 5.3% fall versus an implied move of 3.5%.
- November 2024 brought a 3.7% decline with an implied move of 3.1%.
- August 2024 earnings pushed shares up 5.2% versus an implied move of 3.8%.
- May 2024 experienced a 3.9% drop compared to an implied move of 3.8%.
The persistence of larger-than-expected reactions in the majority of those instances suggests that options-implied moves have sometimes underestimated the market’s response to Medtronic’s earnings. Traders and investors monitoring the company going into the June release may want to weigh that historical pattern when assessing risk and positioning around the announcement.
Context and market relevance
Medtronic’s implied move is a snapshot of how options traders are positioning for near-term volatility tied to corporate news. While the figure - in this case 4.1% - represents the market’s expectation, previous post-earnings swings indicate actual outcomes can diverge materially from that expectation.
Given the stock’s track record of frequently exceeding implied moves, market participants in healthcare equities and broader stock-market strategies may see elevated short-term risk around the June 3 report. That risk is reflected across derivatives pricing and could affect intraday liquidity and price discovery during the immediate post-release session.